RemedyBio Completes €10.5M Financing from European Innovation Council
RemedyBio, an immunology focused discovery and development company, today announces the final closing of an additional €8M ($9.4M) in equity financing from the EIC Fund, completing a €10.5M ($12.4M) funding award to the company by the EIC Accelerator. This additional €8M financing complements the EIC grant funding of €2.5M ($3M) already awarded to RemedyBio in June 2020, to develop a Rapid Pandemic Response Platform based on its proprietary Nanoreactor™ platform. This financing follows RemedyBio’s selection from almost 4,000 company proposals submitted to the EIC Accelerator in 2020.
RemedyBio’s technology is designed to rapidly and simultaneously analyze millions of single immune cells from an individual sample. After succeeding in flagging powerful new antibodies against SARS-CoV-2 from the immune system of COVID-19 infected patients, the platform is now being tuned to respond to new variants and future diseases. The aim is to create a rapid passive therapy against new strains of COVID-19 and, primarily, to control future pandemics more rapidly, by making therapies for new viruses available in less than 90 days.
“This financing from the EIC Fund will enable us to advance our technology development and therapeutic discovery activities, and forge collaborations with leading pharma partners and key clinical and research groups,” said Daniel Crowley, CEO of RemedyBio. “We are delighted to have the support of the EIC Fund. It fills an important financing gap, supporting European companies with innovative technologies to create deep scientific programs and commercial partnerships. In our case, this will drive transformative biological insights and new therapy discoveries.”
This investment will fund the significant development of RemedyBio’s innovative, proprietary Nanoreactor platform as well as advancing its key therapeutic pipeline assets. The Nanoreactor platform has been developed by RemedyBio, originating from intellectual property exclusively licensed from Dublin City University (DCU), following a decade-long R&D programme led by Dr. Paul Leonard, the company’s chief scientist and co-founder. The platform has created a step-change in the speed, scale and quality of single cell analysis and discovery, paving the way for powerful new antibodies and cell therapies. Its high-throughput identification capabilities open fresh insights into immune system interactions – driving a new era in precision medicine against viral diseases, cancer and auto-immune disorders.
“At Enterprise Ireland, we welcome this substantial EIC Fund investment in an Irish high potential start-up,” said Garrett Murray, national director for Horizon Europe at Enterprise Ireland. “RemedyBio is a great example of an Irish company that has succeeded in winning competitive funding through the EIC and, in Ireland, through the Disruptive Technology Innovation Fund (DTIF) for oncology cell therapy applications, to help fund its development and advance its scaling strategy. Enterprise Ireland is here to support and advise ambitious and innovative Irish start-ups considering application for competitive EIC financing as part of their funding journey.”
Heidi Kakko, member of the Investment Committee of the European Innovation Council Fund said, “This financing round will enable Remedy Biologics to develop a Rapid COVID-19 Passive Therapy Response Platform. We are glad the EIC Fund is supporting this breakthrough company, which is playing a pioneering role in creating new solutions in immune therapeutics. This shows how the EU contribution is crucial in tackling the Covid19 response.”
People In This Post
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more